Healthcare Triangle Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Summary Compensation Table
The following summary compensation table provides information regarding the compensation paid during our fiscal years ended December 31, 2023, and 2022 to our Chief Financial Officer, Head of Strategic Partnership and our Head of M&A. We refer to these individuals as our “named executive officers.”:
| Option | |||||
|---|---|---|---|---|---|
| Name and Principal Position | Year | (Salary $) | (Bonus $) | Awards($) | Total ($) |
| Thyagarajan Ramachandran | 2023 | 217,500 | 50,000 | 27,803 | 295,303 |
| Chief Financial Officer | 2022 | 121,035 | — | 24,282 | 145,317 |
| Lakshmanan Kannappan | 2023 | 198,000 | 10,000 | 8,484 | 216,484 |
| Head of Strategic Partnership | 2022 | 198,000 | 2,008 | 200,008 | |
| Shibu Kizhakevilayil | 2023 | 229,884 | 8,484 | 238,368 | |
| Head of M&A | 2022 | 229,884 | 25,000 | 2,008 | 256,892 |
Outstanding Equity Awards at Fiscal Year-End
The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2023.
| Number of Securities · Number of Securities | |||||
|---|---|---|---|---|---|
| Underlying · Underlying | |||||
| Unexercised Options · Unexercised Options · Option Exercise · Option Expiration | |||||
| Name | Grant Date | (#) Exercisable | (#) Unexercisable | Price ($) | Date |
| Thyagarajan Ramachandran | 01/01/2021 | 7,500 | 5,625 | 4.00 | 01/01/2031 |
| Thyagarajan Ramachandran | 11/09/2022 | 17,500 | 7,500 | 1.90 | 11/09/2027 |
| Thyagarajan Ramachandran | 03/20/2023 | 25,000 | 8,333 | 3.30 | 03/19/2028 |
| Lakshmanan Kannappan | 12/31/2021 | 5,000 | 3,750 | 4.00 | 01/01/2031 |
| Lakshmanan Kannappan | 03/20/2023 | 15,000 | 7,500 | 3.30 | 03/19/2028 |
| Shibu Kizhakevilayil | 12/31/2021 | 5,000 | 3,750 | 4.00 | 01/01/2031 |
| Shibu Kizhakevilayil | 03/20/2023 | 15,000 | 7,500 | 3.30 | 03/19/2031 |
Director Compensation Table
The following table provides information concerning compensation paid to our directors during fiscal year ended December 31, 2023.
| Fee Earned / Paid | ||||
|---|---|---|---|---|
| Name | in Cash $ | Options | Others | Total $ |
| Dave Rosa | 92,633 | 69,800 | — | 162,433 |
| Mohammad Jainal Bhuiyan | 36,997 | 19,700 | — | 56,697 |
| Ronald McClurg | 47,047 | 19,700 | — | 66,747 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.